A Phase 2 Repeat-Dosing Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis.
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2017
At a glance
- Drugs SB 509 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- 28 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Nov 2010 Results were presented at the Society for Neuroscience Annual Meeting, according to a Sangamo BioSciences media release.
- 03 Mar 2010 Planned end date changed from 1 May 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.